Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Studying Adhesion Forces Between Cancer Cells

Published: Tuesday, February 18, 2014
Last Updated: Tuesday, February 18, 2014
Bookmark and Share
JPK Instruments reports on the current cancer research project of Dr Florian T Ludwig at the Institute of Physiology II, University Hospital Münster, using a CellHesion® 200 to measure the adhesive forces between tumor cells.

JPK Instruments reports on the current cancer research project of Dr Florian T Ludwig at the Institute of Physiology II, University Hospital Münster, who uses a CellHesion® 200 to measure the adhesive forces between tumor cells.

The Institute of Physiology II is part of the Medical Faculty of the Westfälische Wilhelms-Universität Münster. It brings together the areas of physiology, cell migration and ion transporters through the study of properties of cells on the nanoscale.

Dr Florian T Ludwig is a member of the team of Professor Albrecht Schwab and Dr Christian Stock. These researchers are interested in how ion transport across the plasma membrane affects tumor cell motility and, thus, metastasis. Occurring prior to migration and invasion, one early step of the so-called metastatic cascade is the detachment of single tumor cells or cell clusters from the primary neoplasm. This process is accompanied by a controlled loss of cell-cell adhesions caused by the release of bonds between adhesion molecules such as cadherins. Hence, the adhesion force between tumor cells might predict the tumor's malignancy. Tumor cells that exhibit low cell-cell adhesion forces would represent a highly metastatic phenotype since they detach more easily.

With the help of Mike Wälte from the group of the Head of the Institute, Professor Hans Oberleithner and Dr Hermann Schillers, Dr. Ludwig measures cell-cell adhesion forces in tumor cells. This is based on the group's distinguished expertise of nearly two decades' experience in atomic force microscopy, AFM.

For the experiments, a single tumor cell is attached to the cantilever of a JPK CellHesion® 200 system using a bionic cell adhesive. A second, adherent tumor cell is then approached with the cantilever until the two cells come into contact. After a defined contact time, the cantilever is retracted until the two cells are separated. The strength of the cell-cell bonds that formed while the cells were in contact is estimated by recording the force necessary to separate the cells. Here, the key feature of the CellHesion® 200 system is its ability of the cantilever sensor lifting system to travel more than 110 µm giving a clear benefit for the researchers whose aim is to separate two tumor cells both gently, reproducibly and efficiently without damage. With the technique described here, cell-cell adhesion forces can be quantified.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos